Javascript must be enabled to continue!
Clinical utility of CLL-IPI scoring system in Pakistani Chronic Lymphocytic Patients: A single center experience
View through CrossRef
Objectives: To determine validity of the CLL International prognostic index (IPI) scoring system in Pakistani chronic lymphocytic leukemia patients, as the validity and universal applicability of various prognostic scoring systems such as the CLL-IPI remains a challenge, particularly in under-developed countries like Pakistan.
Methods: This prospective single center study was conducted at Department of Hematology, University of Health Sciences, Lahore and included sixty patients with CLL diagnosed between July, 2019 to July, 2022. Patients were followed for a period of two years and 02 year overall survival (OS) was noted. Risk stratification was conducted according to CLL-IPI prognostic model.
Results: Among 60 patients, the mean age was 60±11years. Advanced Binet stage B+C and elevated β2-microglobulin >3.5mg/L was observed in 73.3% and 38.3% patients respectively. The estimated median 02 years OS was 16.5 months (95% CI: 10-20 months). In total, 40 of 60 CLL patients (67%) were accessible for follow-up analyses. For the present CLL cohort, 25% patients (n = 10) were classified as CLL-IPI low risk and intermediate risk group, 35% (n = 14) as high risk and 15% (n = 06) as very high-risk group. However, this classification of patients according to CLL-IPI did not yield significant differences in terms of OS (p = 0.24), although the median OS of CLL-IPI very high-risk group was noted as only six months and was not reached for low and intermediate risk groups.
Conclusion: To conclude, clinical validation of CLL-IPI scoring system could not be established for the present CLL cohort and needs to be evaluated in further studies with larger sample size.
doi: https://doi.org/10.12669/pjms.40.4.8703
How to cite this: Hameed A, Sajid N, Fayyaz M, Khaliq S. Clinical utility of CLL-IPI scoring system in Pakistani Chronic Lymphocytic Patients: A single center experience. Pak J Med Sci. 2024;40(4):701-705. doi: https://doi.org/10.12669/pjms.40.4.8703
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pakistan Journal of Medical Sciences
Title: Clinical utility of CLL-IPI scoring system in Pakistani Chronic Lymphocytic Patients: A single center experience
Description:
Objectives: To determine validity of the CLL International prognostic index (IPI) scoring system in Pakistani chronic lymphocytic leukemia patients, as the validity and universal applicability of various prognostic scoring systems such as the CLL-IPI remains a challenge, particularly in under-developed countries like Pakistan.
Methods: This prospective single center study was conducted at Department of Hematology, University of Health Sciences, Lahore and included sixty patients with CLL diagnosed between July, 2019 to July, 2022.
Patients were followed for a period of two years and 02 year overall survival (OS) was noted.
Risk stratification was conducted according to CLL-IPI prognostic model.
Results: Among 60 patients, the mean age was 60±11years.
Advanced Binet stage B+C and elevated β2-microglobulin >3.
5mg/L was observed in 73.
3% and 38.
3% patients respectively.
The estimated median 02 years OS was 16.
5 months (95% CI: 10-20 months).
In total, 40 of 60 CLL patients (67%) were accessible for follow-up analyses.
For the present CLL cohort, 25% patients (n = 10) were classified as CLL-IPI low risk and intermediate risk group, 35% (n = 14) as high risk and 15% (n = 06) as very high-risk group.
However, this classification of patients according to CLL-IPI did not yield significant differences in terms of OS (p = 0.
24), although the median OS of CLL-IPI very high-risk group was noted as only six months and was not reached for low and intermediate risk groups.
Conclusion: To conclude, clinical validation of CLL-IPI scoring system could not be established for the present CLL cohort and needs to be evaluated in further studies with larger sample size.
doi: https://doi.
org/10.
12669/pjms.
40.
4.
8703
How to cite this: Hameed A, Sajid N, Fayyaz M, Khaliq S.
Clinical utility of CLL-IPI scoring system in Pakistani Chronic Lymphocytic Patients: A single center experience.
Pak J Med Sci.
2024;40(4):701-705.
doi: https://doi.
org/10.
12669/pjms.
40.
4.
8703
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/3.
0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Related Results
Impact of Atrial Fibrillation on Cardiovascular and Economic Outcomes in Patients with Chronic Lymphocytic Leukemia
Impact of Atrial Fibrillation on Cardiovascular and Economic Outcomes in Patients with Chronic Lymphocytic Leukemia
Abstract
Introduction: Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed hematologic cancer, with many patients diagnosed at a later stage in life ...
Different Pattern of CD154 and CD40 Expression On B-CLL and T Lymphocytes In Peripheral Blood, Bone Marrow and Lymph Node Microenvironment In B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Different Pattern of CD154 and CD40 Expression On B-CLL and T Lymphocytes In Peripheral Blood, Bone Marrow and Lymph Node Microenvironment In B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Abstract
Abstract 3607
Background:
In B-cell chronic lymphocytic leukemia (B-CLL) there is a well documented intr...
Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients
Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients
Abstract
Background CD8+ T cells from chronic lymphocytic leukemia (CLL) patients have been demonstrated to exhibit a number of alterations in global gene expression...
Abstract 4560: Targeting chronic lymphocytic leukemia with p53 deficiency with phenethyl isothiocyanate
Abstract 4560: Targeting chronic lymphocytic leukemia with p53 deficiency with phenethyl isothiocyanate
Abstract
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States and Europe. Despite recent advance in new therapeutic agents that ...
Cell-Derived Microparticle (C-MP) Profiles in Lymphoproliferative Disorders: Association of Elevated Red Cell Microparticles (RMP) with Thrombosis.
Cell-Derived Microparticle (C-MP) Profiles in Lymphoproliferative Disorders: Association of Elevated Red Cell Microparticles (RMP) with Thrombosis.
Abstract
INTRODUCTION: Lymphoproliferative diseases embrace a variety of disorders including chronic lymphocytic leukemia (CLL), lymphomas and multiple myeloma (MM)....
Cytogenetic abnormalities in mesenchymal stem cells in chronic lymphocytic leukemia (CLL) patients and normal subjects
Cytogenetic abnormalities in mesenchymal stem cells in chronic lymphocytic leukemia (CLL) patients and normal subjects
e22002 Background: Mesenchymal stem cells (MSC) residing in the marrow support hematopoiesis and protect cancer cells from undergoing cell death induced by chemotherapy. Recent re...
Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment
Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment
Background : Patients with Chronic Lymphocytic Leukemia (CLL) are susceptible to infections due to impaired immunity, from both complications of disease and treatments. Specific tr...
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia
Abstract
Approximately half of patients with chronic lymphocytic leukemia (CLL) will never require treatment; nonetheless, they are recommended life-long speciali...

